76 results about "Canine kidney" patented technology

The invention discloses application of ginkgolide B to preparation of medicament for preventing and / or treating autosomal dominant polycystic kidney disease. A madin-darby canine kidney (MDCK) vesicle model is used for screening to find that the ginkgolide B inhibits formation and growth of vesicles. An experimental result shows that: the ginkgolide B has an obvious inhibiting effect on the formation and growth of MDCK vesicles and the effect of the ginkgolide B is in dose response relationship; the ginkgolide B has no cytotoxicity to MDCK cells, so that the vesicle inhibiting effect of the ginkgolide B is independent of the cytotoxicity; the ginkgolide B does not obviously induce MDCK cell apoptosis, so that the vesicle inhibiting effect of the ginkgolide B is independent of cell apoptosis promotion of the ginkgolide B; the ginkgolide B can promote the MDCK cells or vesicles to form tubular structures; and the effect is in dose response relationship; and the ginkgolide B has an inhibiting effect on the growth of the embryonic kidney vesicles. The ginkgolide B provides experimental data for development of a specific medicament for preventing and / or treating autosomal dominant polycystic kidney disease.

The invention provides applications of poly mannuronic acid propyl ester sulfate (PMS) in preparing anti- H1N1 influenza A virus medication. Experiments of the invention prove that PMS not only has great inhibition effect on the neuraminidase of the influenza A virus, but also has relatively good protection effect on canine kidney epithelial cells infected with the H1N1 influenza A virus, and can reduce the replication of the H1N1 virus with an effect that equal to the positive control medication ribavirin. Additionally, the PMS can effectively reduce the death rate of mice infected with the H1N1 influenza A virus and the survival time of the mice are prolonged. The poly mannuronic acid propyl ester sulfate provided by the invention has significant activity of inhibiting the neuraminidase of the H1N1 influenza A virus, and is proved to have good anti- H1N1 influenza A virus activity both in vivo and in vitro experiments, which shows the wide application prospect of the poly mannuronic acid propyl ester sulfate in preparing anti-H1N1 influenza A virus medication.

The invention discloses a method for producing a vaccine for avian influenza viruses and other influenza viruses such as a swine influenza virus, a canine influenza virus and an equine influenza virus. The method comprises the following steps of: subculturing cells for preparing the vaccine; (2) reproducing cytotoxic varieties; (3) performing microcarrier suspension culture on darby canine kidney (MDCK) cells in a bioreactor; (4) reproducing venom for preparing the vaccine; and (5) harvesting virus liquid. The method has the advantages of great reduction in production cost, short production period, no restriction to raw material supply, small occupied area, easy and quick expansion in production scale, low and readily treated environmental pollution, high degree of automation, few labors, easy equilibrium and stabilization in quality and obvious improvement on the yield and the quality of the vaccines.

The invention provides a culture medium suitable for large-scale high-density cultivation of MDCK (Madin Darby Canine Kidney) cells for preparation of influenza vaccine.

Disclosed is a Madin-Darby canine kidney (MDCK)-derived cell line. The MDCK-derived cell line is derived from MDCK cells deposited under accession number ATCC CCL-34. The MDCK-derived cell line can be prepared by serum-free culture and suspension culture. Preferably, the MDCK-derived cell line has low or no tumorigenicity. The MDCK-derived cell line is preferably selected from MDCK Sky1023, MDCK Sky10234 and MDCK Sky3851. Further disclosed are a culture method for growing the MDCK-derived cells and a method for producing a vaccine virus using the MDCK-derived cells.

The present invention relates to a commercial-scale process for the production of influenza virus or antigens for prophylactic, diagnostic, immunotherapeutic or therapeutic purposes. Particularly, the invention provides a Madin-Darby Canine Kidney (MDCK)-derived, cell line and a cell culture-based process for the production of an influenza vaccine and more particularly, a human vaccine comprising influenza types A and B.

Disclosed is a Madin-Darby canine kidney (MDCK)-derived cell line. The MDCK-derived cell line is derived from MDCK cells deposited under accession number ATCC CCL-34. The MDCK-derived cell line can be prepared by serum-free culture and suspension culture. Preferably, the MDCK-derived cell line has low or no tumorigenicity. The MDCK-derived cell line is preferably selected from MDCK Sky1023, MDCK Sky10234 and MDCK Sky3851. Further disclosed are a culture method for growing the MDCK-derived cells and a method for producing a vaccine virus using the MDCK-derived cells.

The invention discloses a traditional Chinese medicine for treating rheumatic lumbocrural pain, comprising the following bulk drugs in parts by weight: 400 parts of rehmannia glutinosa, 200 parts of Chinese yam, 150 parts of poria cocos, 200 parts of common macrocarpium fruit, 150 parts of tree peony bark, 150 parts of oriental waterplantain rhizome, 50 parts of cinnamon, 50 parts of monkshood, 100 parts of cortex eucommiae, 100 parts of radix achyranthis bidentatae, 100 parts of astragalus membranaceus, 20 parts of ephedra root, 50 parts of male silk moth, a couple of geckoes, 350 parts of pizzle, 600 parts of canine kidney, 50 parts of cornu cervi pantotrichum, 50 parts of palmleaf raspberry fruit, 20 parts of cinnabar, 100 parts of cynomorium songaricum, 50 parts of tuner onion seed, 50 parts of fossil fragments, 50 parts of oyster shell, 50 parts of pericarpium citri reticulatae, 100 parts of medicinal Indian mulberry, 100 parts of actinolite, 100 parts of epimedium, 50 parts of leech and the like. The medicine can dispel wind and eliminate dampness, reinforce kidney to strengthen yang, clear liver and improve vision, improve blood circulation, diminish inflammation and relieve pain and has obvious efficacies of treating diseases such as limb weakness and night sweat caused by lumbocrural pain, kidney coldness, waist pain and joint inflammation; the medicine is short in course of treatment and rapid in healing, and has no toxic and side effects; and by using the medicine, the diseases can be thoroughly and radically treated, and can not be relapsed.

The invention discloses application of germacrone in preparation of a medicament for treating or preventing influenza viruses. The cell toxicity of the germacrone on madin-darby canine kidney (MDCK) cells is detected, and the result shows that CC50 is more than 250 microns. The influence of the germacrone on the expression of three antigens and the influence of germacrone on virus genome reproduction are detected, and the result shows that the germacrone formulation inhibits the expression of the virus antigens and the virus genome reproduction with dependency. The virus activity resistant mechanism of the germacrone is preliminarily researched. The virus activity resistance stage of the germacrone in a single reproduction period of the influenza viruses is researched by administration experiments of different time, and the result shows that the germacrone has inhibiting effect on adsorption, entry and early reproduction of the viruses. Moreover, the virus activity resistance of the germacrone to amantadine medicament resistant strains, B-type influenza virus strains and A-type influenza virus H3N2 subtype strains is detected, and the result shows that the germacrone has virus activity resistance to the three kinds of virus strains. The germacrone has the effects of relieving cough, relieving asthma and the like.

The invention discloses a recombinant equine influenza virus strain, a preparation method thereof and a vaccine prepared from the recombinant equine influenza virus strain. The recombinant influenza virus strain contains genes HA and NA of an equine influenza virus A / equine / xinjiang / 3 / 07 (H3N8) strain and six internal genes PB2, PB1, PA, NP, M and NS of an influenza virus A / Puerto Rico / 8 / 34 / Mount Sinai (H1N1) or A / PR / 8 / 34 (H1N1 short for PR8 virus). The recombinant equine influenza virus strain disclosed by the invention is named as rH3N8-PR and is preserved with the number of CGMCC NO.8161. The invention also discloses a preparation method of the recombinant equine influenza virus strain and a vaccine prepared from the recombinant equine influenza virus strain. Compared with a parental strain, the recombinant equine influenza virus strain disclosed by the invention can generate very high virus titer and blood clotting titer on both chick embryos and MDCK (Madin Darby Canine Kidney) cells, and the pathogenicity of the recombinant equine influenza virus strain to mice is remarkably reduced; experiments prove that the vaccine prepared from the recombinant equine influenza virus strain disclosed by the invention has favorable immunogenicity and protective effect.

The invention provides applications of poly mannuronic acid propyl ester sulfate (PMS) in preparing anti- H1N1 influenza A virus medication. Experiments of the invention prove that PMS not only has great inhibition effect on the neuraminidase of the influenza A virus, but also has relatively good protection effect on canine kidney epithelial cells infected with the H1N1 influenza A virus, and can reduce the replication of the H1N1 virus with an effect that equal to the positive control medication ribavirin. Additionally, the PMS can effectively reduce the death rate of mice infected with the H1N1 influenza A virus and the survival time of the mice are prolonged. The poly mannuronic acid propyl ester sulfate provided by the invention has significant activity of inhibiting the neuraminidase of the H1N1 influenza A virus, and is proved to have good anti- H1N1 influenza A virus activity both in vivo and in vitro experiments, which shows the wide application prospect of the poly mannuronic acid propyl ester sulfate in preparing anti-H1N1 influenza A virus medication.